Evidence map›Paper›PMID 28857075›Full record

ReviewNature reviews. Clinical oncology2018

Chimeric antigen receptor T-cell therapies for lymphoma.

Jennifer N Brudno, James N Kochenderfer

Open access · greenAbstract readMulticenter StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 308 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
308citing papers in PubMed, 3 pooled it
27.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

308 citing papers in PubMed, 3 syntheses or guidelines pooled it, 512 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

248 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jennifer N BrudnoExperimental Transplantation and Immunology Branch, National Cancer Institute, NIH Building 10 room 3-3330, Bethesda, Maryland 20892, USA.
James N KochenderferExperimental Transplantation and Immunology Branch, National Cancer Institute, NIH Building 10 room 3-3330, Bethesda, Maryland 20892, USA.
National Cancer Institute · US

Funding

New Chimeric Antigen Receptors for Treating Hematologic MalignanciesZIABC011417 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2011 to 2025
$8.3M
Intramural NIH HHS Z99 CA999999NIH HHS LIG OD033989
6 · The paper itself

Abstract

New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and relapse after autologous stem-cell transplantation are indicators of an especially poor prognosis. Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment modality for these patients. Clinical trial data have demonstrated the potent activity of anti-CD19 CAR T cells against multiple subtypes of B-cell lymphoma, including diffuse large-B-cell lymphoma (DLBCL), follicular lymphoma, mantle-cell lymphoma, and marginal-zone lymphoma. Importantly, anti-CD19 CAR T cells have impressive activity against chemotherapy-refractory lymphoma, inducing durable complete remissions lasting >2 years in some patients with refractory DLBCL. CAR-T-cell therapies are, however, associated with potentially fatal toxicities, including cytokine-release syndrome and neurological toxicities. CAR T cells with novel target antigens, including CD20, CD22, and κ-light chain for B-cell lymphomas, and CD30 for Hodgkin and T-cell lymphomas, are currently being investigated in clinical trials. Centrally manufactured CAR T cells are also being tested in industry-sponsored multicentre clinical trials, and will probably soon become a standard therapy. Herein, we review the clinical efficacy and toxicity of CAR-T-cell therapies for lymphoma, and discuss their limitations and future directions with regard to toxicity management, CAR designs and CAR-T-cell phenotypes, conditioning regimens, and combination therapies.

Indexed as

Antigens, CD19HumansImmunotherapy, AdoptiveKi-1 AntigenLymphomaReceptors, Antigen, T-CellAntigens, CD19CD19-specific chimeric antigen receptorKi-1 AntigenReceptors, Antigen, T-Cell

Identifiers

PMID28857075
PMCPMC12145160
OpenAlexW2751416367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.